Analyte | RIF Period | RSV Period | Coadministration of RIF and RSV Period | ||
---|---|---|---|---|---|
AUC(0–24h) | AUC(0–24h) Ratio (Versus RSV Period) | AUC(0–24h) | AUC(0–24h) | AUC(0–24h) Ratio (Versus RSV Period) | |
μM*h | Geometric Mean (90% CI) | μM*h | μM*h | Geometric Mean (90% CI) | |
DCA | 3.8 ± 2.3 | 3.2 (0.94, 11) | 2.0 ± 1.9 | 2.5 ± 2.7 | 0.95 (0.57, 1.6) |
CA | 3.9 ± 1.8 | 1.6 (1.3, 1.9) | 2.7 ± 1.2 | 3.4 ± 1.8 | 1.3 (0.97, 1.8) |
CDCA | 3.7 ± 2.3 | 1.1 (0.61, 2.1) | 4.1 ± 3.6 | 5.0 ± 4.7 | 1.0 (0.58, 1.8) |
GCA | 4.1 ± 2.1 | 2.3 (1.8, 2.8) | 2.0 ± 1.1 | 3.5 ± 3.0 | 1.7 (1.3, 2.1) |
GDCA | 19.7 ± 5.2 | 7.4 (3.1, 17.4) | 3.7 ± 2.7 | 9.4 ± 8.1 | 1.9 (1.0, 3.7) |
GCDCA | 136.7 ± 61.5 | 1.8 (1.5, 2.2) | 78.6 ± 40.1 | 142.7 ± 114.7 | 1.6 (1.3, 2.0) |
GUDCA | 8.8 ± 3.8 | 1.1 (0.61, 2.2) | 9.2 ± 8.6 | 23.7 ± 31.3 | 1.9 (0.81, 4.6) |
LCA | 1.6 ± 0.36 | 0.90 (0.78, 1.0) | 1.8 ± 0.33 | 1.5 ± 0.35 | 0.86 (0.75, 0.99) |
TCA | 3.7 ± 4.0 | 2.0 (1.6, 2.6) | 2.2 ± 2.7 | 4.3 ± 4.2 | 2.2 (1.5, 3.2) |
TDCA | 1.8 ± 0.79 | 4.8 (2.4, 9.6) | 0.58 ± 0.69 | 1.3 ± 1.3 | 2.1 (1.3, 3.4) |
TCDCA | 11.0 ± 7.9 | 1.8 (1.6, 2.1) | 6.4 ± 4.3 | 13.4 ± 9.0 | 2.0 (1.5, 2.7) |
THDCA/TUDCA | 0.38 ± 0.19 | 1.4 (0.82, 2.4) | 0.33 ± 0.26 | 0.45 ± 0.26 | 2.1 (1.6, 2.8) |
UDCA/HDCA | 0.56 ± 0.30 | 0.66 (0.31, 1.4) | 1.2 ± 1.2 | 0.56 ± 0.34 | 0.97 (0.66, 1.4) |
DHEAS | 92.3 ± 48.2 | 0.97 (0.89, 1.1) | 101.5 ± 45.5 | 97.1 ± 44.4 | 1.0 (0.95, 1.1) |
HDA | 1.9 ± 0.82 | 2.2 (1.8, 2.6) | 0.90 ± 0.37 | 2.2 ± 0.53 | 2.5 (2.1, 3.0) |
TDA | 1.3 ± 0.51 | 2.8 (2.2, 3.5) | 0.47 ± 0.26 | 1.5 ± 0.49 | 3.2 (2.4, 4.2) |
CP Ia | 0.084 ± 0.019 | 4.0 (3.7, 4.5) | 0.021 ± 0.005 | 0.084 ± 0.016 | 4.0 (3.7, 4.3) |
CP IIIa | 0.013 ± 0.004 | 3.4 (2.9, 4.1) | 0.004 ± 0.001 | 0.013 ± 0.003 | 3.5 (3.0, 4.0) |
RSVa | 0.08 ± 0.03 | 0.37 ± 0.12 | 4.8 (4.0, 5.7) |
CI, confidence interval.
↵a Data on plasma CP I, CP III, and RSV concentrations in healthy subjects are from a previous publication (Lai et al., 2016).